Announcements Trials
Browse Landscape

Phase

Phase 4 3

Status

Unknown 2Completed 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Carcinoma, Hepatocellular 11Hepatitis B 10Lymphoma, Non-Hodgkin 3Lymphoma 3Hepatitis B, Chronic 3Stomach Neoplasms 1Recurrence 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Arthritis, Rheumatoid 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma × entecavir × Clear all
NCT01765231 2017-01-10

Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma

Peking University

Phase 4 Unknown
190 enrolled
Lymphoid

Hepatitis B, Lymphoma

NCT01768195 2017-01-10

Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy

Peking University

Phase 4 Unknown
80 enrolled
Lymphoid

Hepatitis B, Lymphoma

NCT00926757 2013-05-29

HBVNHL

Taipei Veterans General Hospital, Taiwan

Phase 4 Completed
80 enrolled
Lymphoid

Hepatitis B, Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡